ATE390915T1 - Sprühgetrocknete insulin-mikropartikel zur inhalation - Google Patents

Sprühgetrocknete insulin-mikropartikel zur inhalation

Info

Publication number
ATE390915T1
ATE390915T1 AT99928111T AT99928111T ATE390915T1 AT E390915 T1 ATE390915 T1 AT E390915T1 AT 99928111 T AT99928111 T AT 99928111T AT 99928111 T AT99928111 T AT 99928111T AT E390915 T1 ATE390915 T1 AT E390915T1
Authority
AT
Austria
Prior art keywords
inhalation
spray dried
dried insulin
insulin microparticles
microparticles
Prior art date
Application number
AT99928111T
Other languages
English (en)
Inventor
Stuart Robinson
Susan Smith
Original Assignee
Quadrant Drug Delivery Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Quadrant Drug Delivery Ltd filed Critical Quadrant Drug Delivery Ltd
Application granted granted Critical
Publication of ATE390915T1 publication Critical patent/ATE390915T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A61K38/063—Glutathione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4826—Trypsin (3.4.21.4) Chymotrypsin (3.4.21.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1688—Processes resulting in pure drug agglomerate optionally containing up to 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT99928111T 1998-06-30 1999-06-28 Sprühgetrocknete insulin-mikropartikel zur inhalation ATE390915T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9814172.4A GB9814172D0 (en) 1998-06-30 1998-06-30 Formulation for inhalation

Publications (1)

Publication Number Publication Date
ATE390915T1 true ATE390915T1 (de) 2008-04-15

Family

ID=10834700

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99928111T ATE390915T1 (de) 1998-06-30 1999-06-28 Sprühgetrocknete insulin-mikropartikel zur inhalation

Country Status (14)

Country Link
EP (1) EP1091729B1 (de)
JP (1) JP2002519315A (de)
CN (1) CN1198582C (de)
AT (1) ATE390915T1 (de)
AU (1) AU752563B2 (de)
BR (1) BR9911697A (de)
CA (1) CA2336376C (de)
DE (1) DE69938452T2 (de)
DK (1) DK1091729T3 (de)
EA (1) EA200100088A1 (de)
ES (1) ES2303378T3 (de)
GB (1) GB9814172D0 (de)
IL (1) IL140306A0 (de)
WO (1) WO2000000176A1 (de)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0441380B1 (de) * 1990-02-08 1996-09-11 Canon Kabushiki Kaisha Bildaufnahmevorrichtung
PT877602E (pt) 1996-01-24 2002-07-31 Byk Gulden Lomberg Chem Fab Processo para o fabrico de composicoes de surfactantes pulmonares em po
US20060165606A1 (en) 1997-09-29 2006-07-27 Nektar Therapeutics Pulmonary delivery particles comprising water insoluble or crystalline active agents
US6565885B1 (en) 1997-09-29 2003-05-20 Inhale Therapeutic Systems, Inc. Methods of spray drying pharmaceutical compositions
US8771740B2 (en) * 1999-12-20 2014-07-08 Nicholas J. Kerkhof Process for producing nanoparticles by spray drying
US7871598B1 (en) 2000-05-10 2011-01-18 Novartis Ag Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery and methods of use
AU2001254995A1 (en) * 2000-05-15 2001-11-26 Vectura Limited Method of manufacturing particles
GB0011807D0 (en) * 2000-05-16 2000-07-05 Quadrant Holdings Cambridge Formulation for inhalation
US7575761B2 (en) 2000-06-30 2009-08-18 Novartis Pharma Ag Spray drying process control of drying kinetics
CA2418960A1 (en) * 2000-08-07 2002-02-14 Inhale Therapeutic Systems, Inc. Inhaleable spray dried 4-helix bundle protein powders having minimized aggregation
US20070122353A1 (en) 2001-05-24 2007-05-31 Hale Ron L Drug condensation aerosols and kits
ATE415155T1 (de) 2001-05-24 2008-12-15 Alexza Pharmaceuticals Inc Verabreichung von alprazolam, estazolam, midazolam oder triazolam durch inhalation
US7498019B2 (en) 2001-05-24 2009-03-03 Alexza Pharmaceuticals, Inc. Delivery of compounds for the treatment of headache through an inhalation route
US20030051728A1 (en) 2001-06-05 2003-03-20 Lloyd Peter M. Method and device for delivering a physiologically active compound
US7585493B2 (en) 2001-05-24 2009-09-08 Alexza Pharmaceuticals, Inc. Thin-film drug delivery article and method of use
US7090830B2 (en) 2001-05-24 2006-08-15 Alexza Pharmaceuticals, Inc. Drug condensation aerosols and kits
JP2005503425A (ja) 2001-05-24 2005-02-03 アレックザ モレキュラー デリヴァリー コーポレイション 所定の吸入ルートによる薬剤エステルの送出
WO2002094242A1 (en) 2001-05-24 2002-11-28 Alexza Molecular Delivery Corporation Delivery of rizatriptan or zolmitriptan through an inhalation route
US7458374B2 (en) 2002-05-13 2008-12-02 Alexza Pharmaceuticals, Inc. Method and apparatus for vaporizing a compound
US7078016B2 (en) 2001-11-21 2006-07-18 Alexza Pharmaceuticals, Inc. Delivery of caffeine through an inhalation route
US20080026068A1 (en) * 2001-08-16 2008-01-31 Baxter Healthcare S.A. Pulmonary delivery of spherical insulin microparticles
WO2003041693A1 (en) 2001-11-09 2003-05-22 Alexza Molecular Delivery Corporation Delivery of diazepam through an inhalation route
PT1458360E (pt) 2001-12-19 2011-07-13 Novartis Ag Derivados de indole como agonistas do recetor s1p1
US6900317B2 (en) 2002-02-19 2005-05-31 Boehringer Ingelheim Pharma Gmbh & Co. Kg Salts of the CGRP antagonist BIBN4096 and inhalable powdered medicaments containing them
US9339459B2 (en) 2003-04-24 2016-05-17 Nektar Therapeutics Particulate materials
US7550133B2 (en) 2002-11-26 2009-06-23 Alexza Pharmaceuticals, Inc. Respiratory drug condensation aerosols and methods of making and using them
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
US20040234916A1 (en) 2003-05-21 2004-11-25 Alexza Molecular Delivery Corporation Optically ignited or electrically ignited self-contained heating unit and drug-supply unit employing same
EP1734938B1 (de) 2004-03-26 2012-06-20 Universita' Degli Studi Di Parma Stark einatembare insulin-mikroteilchen
US7540286B2 (en) 2004-06-03 2009-06-02 Alexza Pharmaceuticals, Inc. Multiple dose condensation aerosol devices and methods of forming condensation aerosols
EP1781360A1 (de) 2004-08-12 2007-05-09 Alexza Pharmaceuticals, Inc. Aerosol-arzneiabgabevorrichtung mit perkussiv aktivierten wärmepackungen
CN101573133B (zh) 2006-07-31 2014-08-27 诺沃-诺迪斯克有限公司 Peg化延长的胰岛素
RU2524150C2 (ru) 2006-09-22 2014-07-27 Ново Нордиск А/С Аналоги инсулина, устойчивые к протеазам
WO2008112661A2 (en) 2007-03-09 2008-09-18 Alexza Pharmaceuticals, Inc. Heating unit for use in a drug delivery device
JP5496082B2 (ja) * 2007-04-30 2014-05-21 ノボ・ノルデイスク・エー／エス タンパク質組成物を乾燥させる方法、乾燥タンパク質組成物、及び乾燥タンパク質を含有する薬学的組成物
CN101861311A (zh) 2007-07-21 2010-10-13 阿尔巴尼分子研究公司 5-吡啶酮取代的吲唑
US8633152B2 (en) 2007-08-07 2014-01-21 Nanomaterials Technology Pte Ltd Process for making micro-sized protein particles
JP2011504505A (ja) 2007-11-21 2011-02-10 デコード ジェネティクス イーエイチエフ 肺および心血管障害を治療するためのビアリールｐｄｅ４抑制剤
KR101614723B1 (ko) 2008-01-11 2016-04-22 알바니 몰레큘라 리써치, 인크. Ｍｃｈ 길항물질로서 (1-아지논)-치환된 피리도인돌
WO2009112583A2 (en) 2008-03-14 2009-09-17 Novo Nordisk A/S Protease-stabilized insulin analogues
HUE032284T2 (en) 2008-03-18 2017-09-28 Novo Nordisk As Protease-stabilized, acylated insulin analogues
WO2010059836A1 (en) 2008-11-20 2010-05-27 Decode Genetics Ehf Substituted aza-bridged bicyclics for cardiovascular and cns disease
KR20150116466A (ko) 2009-01-26 2015-10-15 이스라엘 인스티튜트 포 바이올로지컬 리서치 이환형 헤테로사이클릭 스피로 화합물
ES2625260T5 (es) 2009-03-26 2020-07-29 Pulmatrix Operating Co Inc Formulaciones de polvo seco y métodos para el tratamiento de enfermedades pulmonares
CN103200938B (zh) 2010-08-30 2018-07-31 普马特里克斯营业公司 干燥粉末配方及用于治疗肺部疾病的方法
WO2012030645A1 (en) 2010-08-30 2012-03-08 Pulmatrix, Inc. Respirably dry powder comprising calcium lactate, sodium chloride and leucine
BR112013007304B1 (pt) 2010-09-29 2021-12-14 Pulmatrix, Inc. Pós secos de cátion de metal monovalente para inalação
PT3470057T (pt) 2010-09-29 2021-12-03 Pulmatrix Operating Co Inc Pós secos catiónicos compreendendo sais de magnésio
CN104364260B (zh) 2012-04-11 2017-02-22 诺和诺德股份有限公司 胰岛素制剂
AU2013388034B2 (en) 2013-04-30 2019-08-15 Aspeya US Inc. Dry powder formulations and methods of use
JP6499184B2 (ja) 2013-10-07 2019-04-10 ノヴォ ノルディスク アー／エス インスリン類似体の新規な誘導体
CN112656780A (zh) 2014-02-20 2021-04-16 奥迪托皮克股份有限公司 用于吸入的干粉制剂
EP4218734A1 (de) 2014-07-31 2023-08-02 Vectura Inc. Trockenpulverformulierungen zur inhalation
PE20210857A1 (es) 2016-12-16 2021-05-18 Novo Nordisk As Composiciones farmaceuticas que contienen insulina
US12214118B2 (en) 2018-02-02 2025-02-04 Alexza Pharmaceuticals, Inc. Electrical condensation aerosol device
CN112135613A (zh) 2018-03-20 2020-12-25 西奈山伊坎医学院 激酶抑制剂化合物和组合物及使用方法
IT201800006336A1 (it) * 2018-06-14 2019-12-14 Glutatione ridotto in forma solida amorfa altamente solubile e processo per ottenerlo
EP3846792A4 (de) 2018-09-06 2022-10-12 Innopharmascreen Inc. Verfahren und zusammensetzungen zur behandlung von asthma oder morbus parkinson
WO2020142485A1 (en) 2018-12-31 2020-07-09 Icahn School Of Medicine At Mount Sinai Kinase inhibitor compounds and compositions and methods of use
US20230158125A1 (en) 2020-04-20 2023-05-25 Sorrento Therapeutics, Inc. Pulmonary Administration of ACE2 Polypeptides

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1227855B (de) * 1960-07-12 1966-11-03 Ichthyol Ges Verfahren zur Herstellung von Enzymkoerpern fuer die Durchfuehrung enzymatischer Reaktionen
DE1517787A1 (de) * 1965-12-06 1970-01-29 Takeda Chemical Industries Ltd Enzympraeparat und Verfahren zu seiner Herstellung
CS180896B1 (en) * 1975-07-22 1978-02-28 Pavel Veber Process for treatment of agents for releasing cells from fabrics and surface of cultivation vessels
US6063910A (en) * 1991-11-14 2000-05-16 The Trustees Of Princeton University Preparation of protein microparticles by supercritical fluid precipitation
US6582728B1 (en) * 1992-07-08 2003-06-24 Inhale Therapeutic Systems, Inc. Spray drying of macromolecules to produce inhaleable dry powders
ATE268605T1 (de) * 1994-03-04 2004-06-15 Genentech Inc Pharmazeutische akzeptabel dnase zusammensetzung
ATE416755T1 (de) * 1994-03-07 2008-12-15 Nektar Therapeutics Verfahren und zusammensetzung für die pulmonale darreichung von insulin

Also Published As

Publication number Publication date
EP1091729B1 (de) 2008-04-02
IL140306A0 (en) 2002-02-10
AU4523399A (en) 2000-01-17
EP1091729A1 (de) 2001-04-18
CA2336376A1 (en) 2000-01-06
DE69938452D1 (de) 2008-05-15
CN1317958A (zh) 2001-10-17
DE69938452T2 (de) 2009-05-07
GB9814172D0 (en) 1998-08-26
DK1091729T3 (da) 2008-07-21
JP2002519315A (ja) 2002-07-02
AU752563B2 (en) 2002-09-19
WO2000000176A1 (en) 2000-01-06
ES2303378T3 (es) 2008-08-01
EA200100088A1 (ru) 2001-06-25
CA2336376C (en) 2008-11-25
CN1198582C (zh) 2005-04-27
BR9911697A (pt) 2001-03-20

Similar Documents

Publication Publication Date Title
ATE390915T1 (de) Sprühgetrocknete insulin-mikropartikel zur inhalation
NZ515392A (en) Respiratory syncytial virus replication inhibitors
YU36302A (sh) Novi tiotropiumski preparati - koji sadrže prah za inhaliranje
MY124329A (en) Active substance concentrate with formoterol, suitable for storage.
EA200101156A1 (ru) ЛЕКАРСТВЕННЫЕ КОМПОЗИЦИИ НОВОГО ТИПА НА ОСНОВЕ ОБЛАДАЮЩИХ ХОЛИНЕРГИЧЕСКИМ ДЕЙСТВИЕМ СОЕДИНЕНИЙ И β-МИМЕТИКОВ
GB0105772D0 (en) Use
MX353044B (es) Liberacion sostenida de anti-infecciosos.
BR9914507A (pt) Concentrado de substância ativa com formoterol, adequado para armazenagem
DK1107737T3 (da) Mikropartikler til anvendelse ved nålelös injektion
CY1110061T1 (el) Συνθεσεις περιλαμβανοντας ενωσεις μοδαφινιλης
WO2002015876A3 (en) Amorphous carrier materials for drug delivery
TW200501935A (en) Use of resveratrol for preparation of a medicament useful for the treatment of influenza virus infections
AU2002332488A8 (en) R-bambuterol, its preparation and therapeutic uses
ATE271852T1 (de) Verbesserte inhalationspräparate
DE60111622D1 (de) Getrennte dosis therapien mit gefässschädigender aktivität
EA200500864A1 (ru) Новый, содержащий тиотропий порошковый препарат для ингаляции
WO2004033484A3 (en) Use of stable glutamine derivatives to improve drug absorption
MXPA01007952A (es) Formulaciones a base de l-arginina para tratar enfermedades, y metodos para usarlas.
EP1297838A4 (de) Pralmorelin-haltige nasentropfen-präparate
BR9701455A (pt) Uso de antagonistas de bradicinina para a preparaçao de medicamentos para o tratamento de doenças fibrogenéticas crônicas do fígado e doenças agudas do fígado
DE60202299D1 (de) Pharmazeutische zusammensetzung enthaltend salmeterol und budesonid zur behandlung von atemkrankheiten
DE60022047D1 (de) Antivirale therapie
RU2000108989A (ru) Способ профилактики и лечения респираторных болезней телят
MX9102702A (es) Administracion de alfa interferon mediante inhalacion oral para tratar asma y enfermedades pulmonarias proliferativas, no malignas.
ATE270886T1 (de) Antivirale therapie

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1091729

Country of ref document: EP

REN Ceased due to non-payment of the annual fee